4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer
Phase 3
Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2012-06-22
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 301
- Registration Number
- NCT01626222
- Locations
- 🇩🇪
Novartis Investigative Site, Wuppertal, Germany
Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
Phase 3
Completed
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Interventions
- Drug: Placebo Comparator
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2017-10-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 106
- Registration Number
- NCT01625182
- Locations
- 🇬🇧
Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom
A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients
Phase 3
Completed
- Conditions
- Liver Transplantation
- Interventions
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 188
- Registration Number
- NCT01625377
- Locations
- 🇫🇷
Novartis Investigative Site, Villejuif, France
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
Phase 2
Terminated
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1
- Registration Number
- NCT01624636
- Locations
- 🇺🇸
Novartis Investigative Site, Cleveland, Ohio, United States
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
Phase 4
Completed
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Drug: Disease Modifying therapy
- First Posted Date
- 2012-06-20
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 881
- Registration Number
- NCT01623596
- Locations
- 🇵🇷
Novartis Investigative Site, Guaynabo, Puerto Rico
ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon
- First Posted Date
- 2012-06-18
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01621269
A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers
- First Posted Date
- 2012-06-18
- Last Posted Date
- 2015-08-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT01621633
- Locations
- 🇩🇪
Novartis Investigative Site, Grunstadt, Germany
Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763
- First Posted Date
- 2012-06-14
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 220
- Registration Number
- NCT01619332
- Locations
- 🇺🇸
Novartis Investigative Site, San Antonio, Texas, United States
Efficacy, Safety and Pharmacokinetics of Artemether-lumefantrine Dispersible Tablet in the Treatment of Malaria in Infants < 5 kg
Phase 2
Completed
- Conditions
- Acute Uncomplicated Falciparum Malaria
- Interventions
- Drug: Artemether-lumefantrine (COA566)
- First Posted Date
- 2012-06-14
- Last Posted Date
- 2015-06-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT01619878
- Locations
- 🇧🇫
Novartis Investigative Site, Burkina Faso, Burkina Faso
🇹🇬Novartis investigative site, Lome, Togo
A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention
Phase 2
Withdrawn
- Conditions
- Patients With Migraine Equal of /More Than 3 and Equal of/ Less Than 12 Migraine Attacks/4 Weeks for Each of the Last 6 Months Preceding the Screening
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01617941
© Copyright 2025. All Rights Reserved by MedPath